Business- Page 42

Healthcare Data and Analytics Organization Hires Head of AI and Promotes New Chief Product Officer FRAMINGHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) — Definitive Healthcare (Nasdaq: DH), a provider of healthcare data

FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members

VERO BEACH, FL, Nov. 04, 2026 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory diseases, today

CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the

Preliminary Results Indicate Election of Two Company Nominees and Three DGB Nominees DANBURY, CT, Nov. 04, 2026 (GLOBE NEWSWIRE) — Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD), a

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) — Electra Therapeutics, Inc. (NASDAQ: ETRA) a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment

Internationally recognized certification validates ROC’s information security management system and controls, which can help streamline security reviews and compliance checks for buyers in highly regulated markets DENVER, CO, Nov. 04, 2026 (GLOBE

CARSON CITY, Nev., Nov. 04, 2026 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company“), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that

ZUSDURI® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth The FDA accepted UroGen’s NDA for UGN-103 (next-generation novel mitomycin-based formulation) for review; PDUFA goal date

DALLAS and MANITOWOC, Wis., Nov. 04, 2026 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX), today announced Sally Washlow and Per Brodin, CEO and CFO, will present at the Southwest IDEAS Investor